請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78985
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 何佳安 | |
dc.contributor.author | Yi-Chun Liu | en |
dc.contributor.author | 劉怡均 | zh_TW |
dc.date.accessioned | 2021-07-11T15:34:18Z | - |
dc.date.available | 2023-08-23 | |
dc.date.copyright | 2018-08-23 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-15 | |
dc.identifier.citation | 1. Epstein, J. I.; Amin, M. B.; Reuter, V. R.; Mostofi, F. K., The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. The American journal of surgical pathology 1998, 22 (12), 1435-48.
2. Jemal, A.; Tiwari, R. C.; Murray, T.; Ghafoor, A.; Samuels, A.; Ward, E.; Feuer, E. J.; Thun, M. J., Cancer statistics, 2004. CA: a cancer journal for clinicians 2004, 54 (1), 8-29. 3. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer 2015, 136 (5), E359-86. 4. Knowles, M. A.; Hurst, C. D., Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature reviews. Cancer 2015, 15 (1), 25-41. 5. Prout, G. R., Jr.; Barton, B. A.; Griffin, P. P.; Friedell, G. H., Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. The Journal of urology 1992, 148 (5), 1413-9. 6. Chamie, K.; Litwin, M. S.; Bassett, J. C.; Daskivich, T. J.; Lai, J.; Hanley, J. M.; Konety, B. R.; Saigal, C. S., Recurrence of high-risk bladder cancer: a population-based analysis. Cancer 2013, 119 (17), 3219-27. 7. Nortier, J. L.; Martinez, M. C.; Schmeiser, H. H.; Arlt, V. M.; Bieler, C. A.; Petein, M.; Depierreux, M. F.; De Pauw, L.; Abramowicz, D.; Vereerstraeten, P.; Vanherweghem, J. L., Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). The New England journal of medicine 2000, 342 (23), 1686-92. 8. Fernandez, D., Hematuria evaluation. Cleveland Clinic journal of medicine 2008, 75 (5), 328; author reply 328. 9. Hafeez, S.; Huddart, R., Advances in bladder cancer imaging. BMC medicine 2013, 11, 104. 10. Goodison, S.; Rosser, C. J.; Urquidi, V., Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Molecular diagnosis & therapy 2013, 17 (2), 71-84. 11. Stamatiou, K.; Papadoliopoulos, I.; Dahanis, S.; Zafiropoulos, G.; Polizois, K., The accuracy of ultrasonography in the diagnosis of superficial bladder tumors in patients presenting with hematuria. Annals of Saudi medicine 2009, 29 (2), 134-7. 12. Turney, B. W.; Willatt, J. M.; Nixon, D.; Crew, J. P.; Cowan, N. C., Computed tomography urography for diagnosing bladder cancer. BJU Int 2006, 98 (2), 345-8. 13. Totaro, A.; Pinto, F.; Brescia, A.; Racioppi, M.; Cappa, E.; D'Agostino, D.; Volpe, A.; Sacco, E.; Palermo, G.; Valentini, A.; Bassi, P., Imaging in bladder cancer: present role and future perspectives. Urologia internationalis 2010, 85 (4), 373-80. 14. Anastasiadis, A.; de Reijke, T. M., Best practice in the treatment of nonmuscle invasive bladder cancer. Therapeutic Advances in Urology 2012, 4 (1), 13-32. 15. Goldman, R. E.; Bajo, A.; MacLachlan, L. S.; Pickens, R.; Herrell, S. D.; Simaan, N., Design and performance evaluation of a minimally invasive telerobotic platform for transurethral surveillance and intervention. IEEE transactions on bio-medical engineering 2013, 60 (4), 918-25. 16. GuhaSarkar, S.; Banerjee, R., Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. Journal of controlled release : official journal of the Controlled Release Society 2010, 148 (2), 147-59. 17. Evans, H. M.; Schulemann, W., THE ACTION OF VITAL STAINS BELONGING TO THE BENZIDINE GROUP. Science (New York, N.Y.) 1914, 39 (1004), 443-54. 18. Steinwall, O.; Klatzo, I., Selective vulnerability of the blood-brain barrier in chemically induced lesions. Journal of neuropathology and experimental neurology 1966, 25 (4), 542-59. 19. Wolman, M.; Klatzo, I.; Chui, E.; Wilmes, F.; Nishimoto, K.; Fujiwara, K.; Spatz, M., Evaluation of the dye-protein tracers in pathophysiology of the blood-brain barrier. Acta neuropathologica 1981, 54 (1), 55-61. 20. Tsopelas, C.; Sutton, R., Why certain dyes are useful for localizing the sentinel lymph node. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2002, 43 (10), 1377-82. 21. Kaya, M.; Ahishali, B., Assessment of permeability in barrier type of endothelium in brain using tracers: Evans blue, sodium fluorescein, and horseradish peroxidase. Methods in molecular biology (Clifton, N.J.) 2011, 763, 369-82. 22. Uyama, O.; Okamura, N.; Yanase, M.; Narita, M.; Kawabata, K.; Sugita, M., Quantitative evaluation of vascular permeability in the gerbil brain after transient ischemia using Evans blue fluorescence. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1988, 8 (2), 282-4. 23. Radu, M.; Chernoff, J., An in vivo assay to test blood vessel permeability. Journal of visualized experiments : JoVE 2013, (73), e50062. 24. Kozler, P.; Pokorny, J., Altered blood-brain barrier permeability and its effect on the distribution of Evans blue and sodium fluorescein in the rat brain applied by intracarotid injection. Physiological research 2003, 52 (5), 607-14. 25. Slama, M.; Susic, D.; Varagic, J.; Ahn, J.; Frohlich, E. D., Echocardiographic measurement of cardiac output in rats. American journal of physiology. Heart and circulatory physiology 2003, 284 (2), H691-7. 26. Maeda, H.; Fang, J.; Inutsuka, T.; Kitamoto, Y., Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003, 3 (3), 319-28. 27. Roller, B. T.; Munson, J. M.; Brahma, B.; Santangelo, P. J.; Pai, S. B.; Bellamkonda, R. V., Evans blue nanocarriers visually demarcate margins of invasive gliomas. Drug delivery and translational research 2015, 5 (2), 116-24. 28. Ozawa, T.; Britz, G. W.; Kinder, D. H.; Spence, A. M.; VandenBerg, S.; Lamborn, K. R.; Deen, D. F.; Berger, M. S., Bromophenol blue staining of tumors in a rat glioma model. Neurosurgery 2005, 57 (5), 1041-7; discussion 1041-7. 29. Maeda, H.; Nakamura, H.; Fang, J., The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013, 65 (1), 71-9. 30. Greish, K., Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods in molecular biology (Clifton, N.J.) 2010, 624, 25-37. 31. Do, J.; Foster, D.; Renier, C.; Vogel, H.; Rosenblum, S.; Doyle, T. C.; Tse, V.; Wapnir, I., Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models. Breast cancer research and treatment 2014, 144 (1), 93-101. 32. Prabhu, S. S.; Broaddus, W. C.; Oveissi, C.; Berr, S. S.; Gillies, G. T., Determination of intracranial tumor volumes in a rodent brain using magnetic resonance imaging, Evans blue, and histology: a comparative study. IEEE transactions on bio-medical engineering 2000, 47 (2), 259-65. 33. Elsen, S.; Lerut, E.; Van Cleynenbreugel, B.; van der Aa, F.; van Poppel, H.; de Witte, P. A., Biodistribution of Evans blue in an orthotopic AY-27 rat bladder urothelial cell carcinoma model: implication for the improved diagnosis of non-muscle-invasive bladder cancer (NMIBC) using dye-guided white-light cystoscopy. BJU Int 2015, 116 (3), 468-77. 34. Walker, G., Adhesion to smooth surfaces by insects — a review. International Journal of Adhesion and Adhesives 1993, 13 (1), 3-7. 35. Henriksen, I.; Green, K. L.; Smart, J. D.; Smistad, G.; Karlsen, J., Bioadhesion of hydrated chitosans: An in vitro and in vivo study. International Journal of Pharmaceutics 1996, 145 (1), 231-240. 36. Harding, S. E., Mucoadhesive interactions. Biochemical Society transactions 2003, 31 (Pt 5), 1036-41. 37. Hombach, J.; Bernkop-Schnurch, A., Mucoadhesive drug delivery systems. Handbook of experimental pharmacology 2010, (197), 251-66. 38. Harding, S. E.; Davis, S. S.; Deacon, M. P.; Fiebrig, I., Biopolymer mucoadhesives. Biotechnology & genetic engineering reviews 1999, 16, 41-86. 39. Bansil, R.; Turner, B. S., Mucin structure, aggregation, physiological functions and biomedical applications. Current Opinion in Colloid & Interface Science 2006, 11 (2), 164-170. 40. Peppas, N. A.; Sahlin, J. J., Hydrogels as mucoadhesive and bioadhesive materials: a review. Biomaterials 1996, 17 (16), 1553-61. 41. Soler, R.; Bruschini, H.; Martins, J. R.; Dreyfuss, J. L.; Camara, N. O.; Alves, M. T.; Leite, K. R.; Truzzi, J. C.; Nader, H. B.; Srougi, M.; Ortiz, V., Urinary glycosaminoglycans as biomarker for urothelial injury: is it possible to discriminate damage from recovery? Urology 2008, 72 (4), 937-42. 42. Andrews, G. P.; Laverty, T. P.; Jones, D. S., Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm 2009, 71 (3), 505-18. 43. Sogias, I. A.; Williams, A. C.; Khutoryanskiy, V. V., Why is chitosan mucoadhesive? Biomacromolecules 2008, 9 (7), 1837-42. 44. Khutoryanskiy, V. V., Advances in mucoadhesion and mucoadhesive polymers. Macromolecular bioscience 2011, 11 (6), 748-64. 45. Bernkop-Schnurch, A., Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev 2005, 57 (11), 1569-82. 46. Bravo-Osuna, I.; Vauthier, C.; Farabollini, A.; Palmieri, G. F.; Ponchel, G., Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 2007, 28 (13), 2233-43. 47. Zhang, Q.; Neoh, K. G.; Xu, L.; Lu, S.; Kang, E. T.; Mahendran, R.; Chiong, E., Functionalized mesoporous silica nanoparticles with mucoadhesive and sustained drug release properties for potential bladder cancer therapy. Langmuir 2014, 30 (21), 6151-61. 48. Wilczewska, A. Z.; Niemirowicz, K.; Markiewicz, K. H.; Car, H., Nanoparticles as drug delivery systems. Pharmacological reports : PR 2012, 64 (5), 1020-37. 49. Nevozhay, D.; Kanska, U.; Budzynska, R.; Boratynski, J., [Current status of research on conjugates and related drug delivery systems in the treatment of cancer and other diseases]. Postepy higieny i medycyny doswiadczalnej (Online) 2007, 61, 350-60. 50. Patel, S.; Bhirde, A. A.; Rusling, J. F.; Chen, X.; Gutkind, J. S.; Patel, V., Nano delivers big: designing molecular missiles for cancer therapeutics. Pharmaceutics 2011, 3 (1), 34-52. 51. Allen, T. M.; Cullis, P. R., Drug delivery systems: entering the mainstream. Science (New York, N.Y.) 2004, 303 (5665), 1818-22. 52. Kobayashi, H.; Brechbiel, M. W., Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev 2005, 57 (15), 2271-86. 53. Kobayashi, H.; Watanabe, R.; Choyke, P. L., Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 2013, 4 (1), 81-9. 54. Maeda, H., Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjugate chemistry 2010, 21 (5), 797-802. 55. Kwon, S.; Singh, R. K.; Perez, R. A.; Abou Neel, E. A.; Kim, H. W.; Chrzanowski, W., Silica-based mesoporous nanoparticles for controlled drug delivery. Journal of tissue engineering 2013, 4, 2041731413503357. 56. Brannon-Peppas, L., Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. International Journal of Pharmaceutics 1995, 116 (1), 1-9. 57. Shchipunov, Y. A.; Burtseva, Y. V.; Karpenko, T. Y.; Shevchenko, N. M.; Zvyagintseva, T. N., Highly efficient immobilization of endo-1,3-β-d-glucanases (laminarinases) from marine mollusks in novel hybrid polysaccharide-silica nanocomposites with regulated composition. Journal of Molecular Catalysis B: Enzymatic 2006, 40 (1), 16-23. 58. Liong, M.; Lu, J.; Kovochich, M.; Xia, T.; Ruehm, S. G.; Nel, A. E.; Tamanoi, F.; Zink, J. I., Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS nano 2008, 2 (5), 889-96. 59. Klichko, Y.; Liong, M.; Choi, E.; Angelos, S.; Nel, A. E.; Stoddart, J. F.; Tamanoi, F.; Zink, J. I., Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. Journal of the American Ceramic Society. American Ceramic Society 2009, 92 (s1), s2-s10. 60. Tourne-Peteilh, C.; Begu, S.; Lerner, D. A.; Galarneau, A.; Lafont, U.; Devoisselle, J.-M., Sol–gel one-pot synthesis in soft conditions of mesoporous silica materials ready for drug delivery system. Journal of Sol-Gel Science and Technology 2012, 61 (3), 455-462. 61. Slowing, II; Vivero-Escoto, J. L.; Wu, C. W.; Lin, V. S., Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008, 60 (11), 1278-88. 62. Trewyn, B. G.; Slowing, II; Giri, S.; Chen, H. T.; Lin, V. S., Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol-gel process and applications in controlled release. Accounts of chemical research 2007, 40 (9), 846-53. 63. Cho, K.; Wang, X.; Nie, S.; Chen, Z. G.; Shin, D. M., Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14 (5), 1310-6. 64. Torchilin, V. P., Passive and active drug targeting: drug delivery to tumors as an example. Handbook of experimental pharmacology 2010, (197), 3-53. 65. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of controlled release : official journal of the Controlled Release Society 2000, 65 (1-2), 271-84. 66. Maeda, H., The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advances in enzyme regulation 2001, 41, 189-207. 67. R. Upponi, J.; Torchilin, V., Passive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors. 2014. 68. Bazak, R.; Houri, M.; El Achy, S.; Kamel, S.; Refaat, T., Cancer active targeting by nanoparticles: a comprehensive review of literature. Journal of cancer research and clinical oncology 2015, 141 (5), 769-84. 69. Allen, T. M., Ligand-targeted therapeutics in anticancer therapy. Nature reviews. Cancer 2002, 2 (10), 750-63. 70. Yu, M. K.; Park, J.; Jon, S., Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012, 2 (1), 3-44. 71. Nahta, R.; Yu, D.; Hung, M.-C.; Hortobagyi, G. N.; Esteva, F. J., Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology 2006, 3, 269. 72. Huh, Y. M.; Jun, Y. W.; Song, H. T.; Kim, S.; Choi, J. S.; Lee, J. H.; Yoon, S.; Kim, K. S.; Shin, J. S.; Suh, J. S.; Cheon, J., In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. Journal of the American Chemical Society 2005, 127 (35), 12387-91. 73. Press, M. F.; Cordon-Cardo, C.; Slamon, D. J., Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990, 5 (7), 953-62. 74. Ni, X.; Castanares, M.; Mukherjee, A.; Lupold, S. E., Nucleic acid aptamers: clinical applications and promising new horizons. Current medicinal chemistry 2011, 18 (27), 4206-14. 75. Farokhzad, O. C.; Jon, S.; Khademhosseini, A.; Tran, T. N.; Lavan, D. A.; Langer, R., Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer research 2004, 64 (21), 7668-72. 76. Yu, M. K.; Kim, D.; Lee, I. H.; So, J. S.; Jeong, Y. Y.; Jon, S., Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small (Weinheim an der Bergstrasse, Germany) 2011, 7 (15), 2241-9. 77. Talekar, M.; Kendall, J.; Denny, W.; Garg, S., Targeting of nanoparticles in cancer: drug delivery and diagnostics. Anti-cancer drugs 2011, 22 (10), 949-62. 78. Elnakat, H.; Ratnam, M., Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004, 56 (8), 1067-84. 79. Mattheolabakis, G.; Milane, L.; Singh, A.; Amiji, M. M., Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. Journal of drug targeting 2015, 23 (7-8), 605-18. 80. Toole, B. P., Hyaluronan: from extracellular glue to pericellular cue. Nature reviews. Cancer 2004, 4 (7), 528-39. 81. Scott, J. E.; Heatley, F., Hyaluronan forms specific stable tertiary structures in aqueous solution: a 13C NMR study. Proceedings of the National Academy of Sciences of the United States of America 1999, 96 (9), 4850-5. 82. Hua, Q.; Knudson, C. B.; Knudson, W., Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis. Journal of cell science 1993, 106 ( Pt 1), 365-75. 83. Knudson, C. B.; Knudson, W., Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1993, 7 (13), 1233-41. 84. Platt, V. M.; Szoka, F. C., Jr., Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008, 5 (4), 474-86. 85. Naor, D.; Sionov, R. V.; Ish-Shalom, D., CD44: structure, function, and association with the malignant process. Advances in cancer research 1997, 71, 241-319. 86. Goodison, S.; Urquidi, V.; Tarin, D., CD44 cell adhesion molecules. Molecular pathology : MP 1999, 52 (4), 189-96. 87. Jothy, S., CD44 and its partners in metastasis. Clinical & experimental metastasis 2003, 20 (3), 195-201. 88. Marhaba, R.; Zoller, M., CD44 in cancer progression: adhesion, migration and growth regulation. Journal of molecular histology 2004, 35 (3), 211-31. 89. Bourguignon, L. Y., Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Seminars in cancer biology 2008, 18 (4), 251-9. 90. Durand, R. E.; Raleigh, J. A., Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer research 1998, 58 (16), 3547-50. 91. Hamilton, G., Multicellular spheroids as an in vitro tumor model. Cancer letters 1998, 131 (1), 29-34. 92. Pampaloni, F.; Reynaud, E. G.; Stelzer, E. H., The third dimension bridges the gap between cell culture and live tissue. Nature reviews. Molecular cell biology 2007, 8 (10), 839-45. 93. Thoma, C. R.; Zimmermann, M.; Agarkova, I.; Kelm, J. M.; Krek, W., 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv Drug Deliv Rev 2014, 69-70, 29-41. 94. Santini, M. T.; Rainaldi, G., Three-dimensional spheroid model in tumor biology. Pathobiology : journal of immunopathology, molecular and cellular biology 1999, 67 (3), 148-57. 95. Haji-Karim, M.; Carlsson, J., Proliferation and viability in cellular spheroids of human origin. Cancer research 1978, 38 (5), 1457-64. 96. Baker, B. M.; Chen, C. S., Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues. Journal of cell science 2012, 125 (Pt 13), 3015-24. 97. Yamada, K. M.; Cukierman, E., Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130 (4), 601-10. 98. Friedrich, J.; Seidel, C.; Ebner, R.; Kunz-Schughart, L. A., Spheroid-based drug screen: considerations and practical approach. Nature protocols 2009, 4 (3), 309-24. 99. Jaganathan, H.; Gage, J.; Leonard, F.; Srinivasan, S.; Souza, G. R.; Dave, B.; Godin, B., Three-dimensional in vitro co-culture model of breast tumor using magnetic levitation. Scientific reports 2014, 4, 6468. 100. D'Hallewin, M. A.; Kamuhabwa, A. R.; Roskams, T.; De Witte, P. A.; Baert, L., Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int 2002, 89 (7), 760-3. 101. Weiswald, L. B.; Bellet, D.; Dangles-Marie, V., Spherical cancer models in tumor biology. Neoplasia (New York, N.Y.) 2015, 17 (1), 1-15. 102. Mayer, B.; Klement, G.; Kaneko, M.; Man, S.; Jothy, S.; Rak, J.; Kerbel, R. S., Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. Gastroenterology 2001, 121 (4), 839-852. 103. Yu, M.; Bardia, A.; Aceto, N.; Bersani, F.; Madden, M. W.; Donaldson, M. C.; Desai, R.; Zhu, H.; Comaills, V.; Zheng, Z.; Wittner, B. S.; Stojanov, P.; Brachtel, E.; Sgroi, D.; Kapur, R.; Shioda, T.; Ting, D. T.; Ramaswamy, S.; Getz, G.; Iafrate, A. J.; Benes, C.; Toner, M.; Maheswaran, S.; Haber, D. A., Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science (New York, N.Y.) 2014, 345 (6193), 216-20. 104. Rajcevic, U.; Knol, J. C.; Piersma, S.; Bougnaud, S.; Fack, F.; Sundlisaeter, E.; Sondenaa, K.; Myklebust, R.; Pham, T. V.; Niclou, S. P.; Jimenez, C. R., Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture. Proteome science 2014, 12, 39. 105. Kondo, J.; Endo, H.; Okuyama, H.; Ishikawa, O.; Iishi, H.; Tsujii, M.; Ohue, M.; Inoue, M., Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 2011, 108 (15), 6235-40. 106. Svatek, R. S.; Hollenbeck, B. K.; Holmäng, S.; Lee, R.; Kim, S. P.; Stenzl, A.; Lotan, Y., The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. European Urology 2014, 66 (2), 253-262. 107. Yao, L.; Xue, X.; Yu, P.; Ni, Y.; Chen, F., Evans Blue Dye: A Revisit of Its Applications in Biomedicine. Contrast Media Mol Imaging 2018, 2018, 7628037. 108. Leitner, V. M.; Walker, G. F.; Bernkop-Schnürch, A., Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. European Journal of Pharmaceutics and Biopharmaceutics 2003, 56 (2), 207-214. 109. Leitner, V. M.; Walker, G. F.; Bernkop-Schnurch, A., Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur J Pharm Biopharm 2003, 56 (2), 207-14. 110. Serretta, V.; Sommatino, F.; Gesolfo, C.; Franco, V.; Cicero, G.; Allegro, R., Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy. Urology Annals 2015, 7 (1), 21-25. 111. Elsen, S.; Lerut, E.; Van Der Aa, F.; Van Cleynenbreugel, B.; Van Poppel, H.; De Witte, P., Evans blue‑mediated white‑light detection of non‑muscle‑invasive bladder cancer: A preclinical feasibility and safety study using a rat bladder urothelial cell carcinoma model. 2016; Vol. 5. 112. Sidaway, P., Blue dye used to selectively label bladder tumours in rats. Nature Reviews Urology 2015, 12, 180. 113. Fang, Y.; Eglen, R. M., Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS discovery : advancing life sciences R & D 2017, 22 (5), 456-472. 114. Madsen, S. J.; Sun, C.-H.; Tromberg, B. J.; Cristini, V.; De Magalhães, N.; Hirschberg, H., Multicell tumor spheroids in photodynamic therapy. Lasers in Surgery and Medicine 2006, 38 (5), 555-564. 115. Dharmaraj, N.; Chapela, P. J.; Morgado, M.; Hawkins, S. M.; Lessey, B. A.; Young, S. L.; Carson, D. D., Expression of the transmembrane mucins, MUC1, MUC4 and MUC16, in normal endometrium and in endometriosis. Human Reproduction 2014, 29 (8), 1730-1738. 116. Stojnev, S.; Ristic-Petrovic, A.; Velickovic, L. J.; Krstic, M.; Bogdanovic, D.; Khanh do, T.; Ristic, A.; Conic, I.; Stefanovic, V., Prognostic significance of mucin expression in urothelial bladder cancer. International journal of clinical and experimental pathology 2014, 7 (8), 4945-58. 117. Simms, M. S.; Hughes, O. D.; Limb, M.; Price, M. R.; Bishop, M. C., MUC1 mucin as a tumour marker in bladder cancer. BJU Int 1999, 84 (3), 350-2. 118. Chan, E.; Patel, A.; Heston, W.; Larchian, W., Mouse orthotopic models for bladder cancer research. BJU Int 2009, 104 (9), 1286-91. 119. Roelants, M.; Huygens, A.; Crnolatac, I.; Van Cleynenbreugel, B.; Lerut, E.; Van Poppel, H.; de Witte, P. A., Evans blue as a selective dye marker for white-light diagnosis of non-muscle-invasive bladder cancer: an in vitro study. BJU Int 2012, 109 (2), 300-5. 120. Misra, S.; Heldin, P.; Hascall, V. C.; Karamanos, N. K.; Skandalis, S. S.; Markwald, R. R.; Ghatak, S., Hyaluronan-CD44 interactions as potential targets for cancer therapy. The FEBS journal 2011, 278 (9), 1429-43. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78985 | - |
dc.description.abstract | 膀胱癌又可以稱做泌尿上皮癌,經由膀胱鏡的診斷區分成肌肉侵入型的膀胱癌和非肌肉侵入型的膀胱癌這兩種形式。泌尿上皮癌又以形成非肌肉侵入型的膀胱癌為主。經尿道膀胱腫瘤切除術 (Transurethral resection of bladder tumor, TURBT)是治療非肌肉侵入型膀胱癌的第一線方法。而選擇性定位膀胱腫瘤對TURBT尤其重要。藉由伊文思藍 (Evans blue, EB) 的膀胱鏡檢查常用於輔助定位膀胱腫瘤的位置,但它在尿液滴注膀胱的期間會被沖刷脫色。因此,迫切需要開發一種替代的成像策略以幫助外科醫生精確定位腫瘤。本論文研究的目的是設計和開發裝載EB的奈米成像系統,藉由增強泌尿上皮的附著,以改善EB在腫瘤部位的滯留和累積量。我們首先製備具有硫醇基的二氧化矽奈米顆粒,由於硫醇基可與黏蛋白 (mucin) 中的半胱胺酸形成雙硫鍵,進而滯留該奈米顆粒於黏膜之上。本研究中藉由IVIS系統分析硫醇基修飾的二氧化矽奈米顆粒所攜帶之EB(EB@MSN-SH)之螢光強度,將對於被EB@MSN-SHEB染色之腫瘤球體,和灌流至小鼠膀胱且模擬尿液沖刷狀況的模式進行觀察。相對於純EB的染色,EB@MSN-SH所釋放之EB可累積在有膀胱癌的小鼠膀胱中,且經過多次沖刷後仍保有較多的EB殘留。從in vitro和in vivo的實驗證實我們的奈米成像系統用於膀胱腫瘤定位的可行性。本論文研究所研發的奈米成像系統具有很大的潛力,可以幫助外科醫生在進行TURBT時定位膀胱腫瘤的位置。 | zh_TW |
dc.description.abstract | Bladder cancer so-called urothelial carcinoma (UCC), can be classified into two types via cystoscopy: one is muscle-invasive bladder cancer (MIBC), the other is non-muscle invasive bladder cancer (NMIBC). The primary form of UCC is the NMIBC. The TURBT remains the first-line treatment for NMIBC. The selective localization of bladder tumor is particularly important for TURBT. Evans Blue (EB) mediated white-light cystoscopy detection was frequently used to aid the detection of bladder tumor, but we often found it destained during the bladder instillation. Thus, it is in urgent need to develop an alternative imaging strategy facilitating surgeon to precisely localize the tumor. This study aims to design and develop the nano-image system that cargo EB and also can enhance the urothelial attachment to prolong the retention time and accumulation in the tumor sites. We designed a thiol-functionalized silica-based nanoparticle, exhibiting mucoadhesivity that was attributed to the formation of a disulfide bond between a thiol-functionalized nanoparticle and cysteine-rich subdomains of mucus. In this study, the EB was loaded into the thiol-functionalized nanoparticles, and subsequently used to stain the NBT-II bladder tumor spheroid or instill into the mouse bladder while mimicking urination. IVIS (in vivo image system) was used herein to monitor the EB fluorescence intensity. Compared to the group stained with free EB, the group treated with thiol-functionalized nanoparticle appeared to accumulated more EB in the bladder of tumor-bearing mice, even after five cycles of instillation. In vitro and in vivo studies were carried out to confirm the feasibility of our nano-imaging system for the location of bladder tumor. Our nano-imaging system holds great potential to aid visualization of superficial bladder tumor for surgeon during transurethral resection. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T15:34:18Z (GMT). No. of bitstreams: 1 ntu-107-R05b22041-1.pdf: 3333533 bytes, checksum: 30d7a2d1aa8999c856b4a88abdbb043c (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 謝誌 i
中文摘要 ii Abstract iii 第一章 緒論 1 1.1. 膀胱癌 1 1.1.1. 膀胱癌簡介及概況 1 1.1.2. 膀胱癌的成因和症狀 2 1.1.3. 膀胱癌的診斷 3 1.1.4. 膀胱癌的治療 4 1.2. 伊文思藍 (Evans blue, EB) 6 1.2.1. Evans Blue的簡介及以往的使用 6 1.2.2. Evans Blue用於標的腫瘤 7 1.3. 黏膜黏附性 8 1.4. 藥物傳輸系統 9 1.4.1. 奈米載體在藥物傳輸系統 9 1.4.2. 中孔洞二氧化矽奈米顆粒 9 1.4.3. 被動與主動標靶 10 1.5. 玻尿酸與CD44的關係 12 1.6. 癌症球狀模型 13 第二章 研究動機與發想 15 第三章 實驗材料、儀器與方法 17 3.1. 實驗藥品、儀器與器材 17 3.1.1. 實驗藥品 17 3.1.2. 細胞株 20 3.1.3. 實驗動物 20 3.1.4. 實驗儀器 20 3.1.5. 實驗器材 22 3.2. 實驗方法 23 3.2.1. 形質轉換 23 3.2.2. 養小量質體 24 3.2.3. 抽小量質體 24 3.2.4. 養大量質體 25 3.2.5. 抽大量質體 25 3.2.6. 細胞繼代培養 26 3.2.7. 細胞冷凍保存 27 3.2.8. 共轉染293T細胞 28 3.2.9. 收集病毒液 29 3.2.10. 病毒感染細胞 30 3.2.11. 建立穩定表現的細胞株 31 3.2.12. 多細胞腫瘤球體模型培養 31 3.2.13. Mucin particle method 33 3.2.14 裝載EB到硫醇基修飾的二氧化矽奈米顆粒MMT-2 34 3.2.15. 硫醇基修飾的矽奈米顆粒裝載EB後的釋放速率 34 3.2.16 建立EB的標準檢量曲線 35 3.2.17. 染色的腫瘤球體經沖刷後EB滯留時間的改變 35 3.2.17.1. 使用多功能微量盤式分析儀偵測腫瘤球體中EB螢光 35 3.2.17.2. 活體冷螢光影像分子影像系統 (IVIS) 觀察腫瘤球體中EB螢光 37 3.2.18. 建立原位膀胱癌小鼠模型 39 3.2.19. 使用小鼠膀胱的黏膜黏附性研究 39 第四章 實驗結果與討論 41 4.1. 建立腫瘤球體 41 4.2. 測試修飾硫醇基的MMT-2黏膜黏附性 44 4.3. 裝載EB並有硫醇基修飾的MMT-2之釋放模式 49 4.4. EB滯留時間的改變 51 4.5. 使用原位膀胱癌小鼠的黏膜黏附性研究 58 第五章 結論與未來展望 64 參考文獻 65 | |
dc.language.iso | zh-TW | |
dc.title | 使用奈米載體輔助專一性鑑定膀胱腫瘤 | zh_TW |
dc.title | Nanomaterial-Assisted Specific Identification of Bladder Tumor | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 徐士蘭,楊家銘,吳立真,鄭豐裕 | |
dc.subject.keyword | 膀胱癌,經尿道膀胱腫瘤切除術,膀胱鏡,伊文思藍,奈米載體, | zh_TW |
dc.subject.keyword | urothelial carcinoma,TURBT,Evans Blue,cystoscopy,nanocarrier, | en |
dc.relation.page | 78 | |
dc.identifier.doi | 10.6342/NTU201803472 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-16 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
dc.date.embargo-lift | 2023-08-23 | - |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-R05b22041-1.pdf 目前未授權公開取用 | 3.26 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。